Comparative Pharmacology
Head-to-head clinical analysis: SANDOSTATIN LAR versus SIGNIFOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SANDOSTATIN LAR versus SIGNIFOR.
SANDOSTATIN LAR vs SIGNIFOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic octapeptide analog of somatostatin with greater metabolic stability and longer duration of action. Inhibits growth hormone (GH) secretion via binding to somatostatin receptors (SSTR2 and SSTR5) on pituitary somatotrophs. Also suppresses insulin-like growth factor-1 (IGF-1), glucagon, and insulin secretion. Reduces splanchnic blood flow and inhibits secretion of gastrointestinal hormones.
Somatostatin analog; inhibits growth hormone (GH), insulin-like growth factor 1 (IGF-1), and other hormones.
Octreotide acetate 20 mg intramuscularly every 4 weeks for acromegaly; 20 mg intramuscularly every 4 weeks for neuroendocrine tumors; may initiate at 10 mg for symptom control of carcinoid syndrome and dose titrate based on response.
Subcutaneous injection: 0.3 mg twice daily; Intravenous bolus: 0.9 mg (for Cushing's disease perioperatively).
None Documented
None Documented
Terminal half-life: 12-14 days for subcutaneous octreotide LAR microspheres; clinical steady state achieved after 2-3 injections.
Terminal elimination half-life is approximately 5-6 hours in healthy subjects. In patients with renal impairment, half-life may be prolonged (up to 10 hours in severe impairment).
Renal: 32% as unchanged drug; biliary/fecal: 60-70% via feces as metabolites and unchanged drug.
Primarily renal (approximately 80% of the dose excreted unchanged in urine), with about 20% eliminated via biliary/fecal routes. Renal clearance accounts for ~70% of total clearance.
Category C
Category C
Somatostatin Analog
Somatostatin Analog